News from elusys therapeutics, inc A wide array of domestic and global news stories; news topics include politics / government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages, as well.

Sep 22, 2014, 11:58 ET
corporate logo. (PRNewsFoto/Elusys Therapeutics, Inc.)

Elusys Announces Results From Three Phase 3 Safety Studies Of Its Anthrax Anti-Toxin, Obiltoxaximab (ETI-204), In Adult Volunteers And Completion Of Its Phase 3 Clinical Development Program

 Elusys Therapeutics, Inc. (Elusys), a biopharmaceutical company developing antibody therapies to treat infectious disease, today announced it...

Apr 08, 2014, 09:00 ET
corporate logo. (PRNewsFoto/Elusys Therapeutics, Inc.)

Elusys Completes Commercial Manufacturing Process Validation for Anthrax Antitoxin ETI-204

 Elusys Therapeutics, Inc. (Elusys), a biopharmaceutical company developing antibody therapies to treat infectious disease, today announced...

Mar 10, 2014, 10:00 ET
corporate logo. (PRNewsFoto/Elusys Therapeutics, Inc.)

Elusys Receives Notice of Allowance from U.S. Patent Office for Methods of Preventing or Treating Anthrax with ETI-204, an Anti-Anthrax Antibody, via Intramuscular Injection

Elusys Therapeutics, Inc. (Elusys), a biopharmaceutical company developing antibody therapies to treat infectious disease, announced that the...

Feb 05, 2014, 09:59 ET
corporate logo. (PRNewsFoto/Elusys Therapeutics, Inc.)

Elusys Completes Enrollment in Three Phase 3 Safety Studies of Its Anthrax Anti-Toxin, ETI-204, in Adult Volunteers

 Elusys Therapeutics, Inc. (Elusys), a biopharmaceutical company developing antibody therapies to treat infectious disease, today...

Sep 05, 2013, 13:30 ET
corporate logo. (PRNewsFoto/Elusys Therapeutics, Inc.)

Elusys Therapeutics Presents Efficacy Results And Other Key Findings On ETI-204 Anthrax Anti-Toxin

 Elusys Therapeutics, Inc. (Elusys), a biopharmaceutical company developing antibody therapies to treat infectious disease, presented key...

Jul 31, 2013, 10:17 ET
corporate logo. (PRNewsFoto/Elusys Therapeutics, Inc.)

Elusys Releases New Data On Anthrax Anti-Toxin Administered Via Intramuscular Injection From Three Recent Animal Studies

 Elusys Therapeutics, Inc. (Elusys), a biopharmaceutical company developing antibody therapies to treat infectious disease, today released...

Sep 13, 2012, 13:54 ET
corporate logo. (PRNewsFoto/Elusys Therapeutics, Inc.)

Elusys Awarded Additional $14.5 Million Under Existing U.S. Government Contracts Supporting Expanded Human Safety Studies of ETI-204 for Treatment of Inhalational Anthrax

Elusys Therapeutics, Inc. (Elusys), a biopharmaceutical company developing countermeasures for biodefense, announced today that it has been...

Aug 02, 2012, 08:30 ET
corporate logo. (PRNewsFoto/Elusys Therapeutics, Inc.)

Elusys Awarded Additional $50.2 Million Under An Existing U.S. Government Contract To Support Final Stages Of Development Of ETI-204, For Treatment Of Inhalational Anthrax

Elusys Therapeutics, Inc. (Elusys), a biopharmaceutical company developing countermeasures for biodefense, announced today that it has been...

Oct 24, 2011, 14:41 ET
corporate logo. (PRNewsFoto/Elusys Therapeutics, Inc.)

Elusys Initiates Third Clinical Safety Study of Anthim, a New Anthrax Treatment; Company Successfully Completes Manufacturing at Commercial Scale

Elusys Therapeutics, Inc. (Elusys), a biopharmaceutical company focused on the development of antibody therapeutics, announced today that it is...

Sep 08, 2011, 10:00 ET
A F ELUSYS THERAPEUTICS, INC. LOGO ELUSYS THERAPEUTICS, INC. LOGO

corporate logo. (PRNewsFoto/Elusys Therapeutics, Inc.)[CH]
 PINE BROOK, NJ UNITED STATES
 04/20/2009

Elusys Awarded $68 Million Contract to Develop Anthim for Intramuscular Pre- and Post-Exposure Prophylaxis of Anthrax Infection

Elusys Therapeutics, Inc. (Elusys), a  biopharmaceutical company developing biodefense countermeasures, announced today that it has been...

Aug 04, 2010, 10:00 ET

Elusys Awarded Additional $40.6 Million Under Existing U.S. Government Contract to Fund Advanced Development of Anthim, a New Treatment for Anthrax

Elusys Therapeutics, Inc. (Elusys), a privately-held biopharmaceutical company, announced today that it has been awarded a second contract year of...

Jul 15, 2010, 09:07 ET
corporate logo. (PRNewsFoto/Elusys Therapeutics, Inc.)

Elusys Therapeutics and Lonza Extend Manufacturing Agreement for Anthim, a New Anthrax Treatment in Late-Stage Development

Elusys Therapeutics and Lonza today announced an agreement for the scale-up and commercial production of Anthim, a therapeutic monoclonal antibody...

Jan 04, 2010, 10:00 ET
A F ELUSYS THERAPEUTICS, INC. LOGO ELUSYS THERAPEUTICS, INC. LOGO

corporate logo. (PRNewsFoto/Elusys Therapeutics, Inc.)[CH]
 PINE BROOK, NJ UNITED STATES
 04/20/2009

Elusys Receives Contract for up to $143 Million from the U.S. Federal Government to Fund Advanced Development of Anthim(R), a New Treatment for Anthrax

Elusys Therapeutics, Inc. (Elusys), a privately-held biopharmaceutical company, announced today that it has signed a contract potentially...

Dec 07, 2009, 09:00 ET
A F ELUSYS THERAPEUTICS, INC. LOGO ELUSYS THERAPEUTICS, INC. LOGO

corporate logo. (PRNewsFoto/Elusys Therapeutics, Inc.)[CH]
 PINE BROOK, NJ UNITED STATES
 04/20/2009

Elusys Presents Data From Anthim(R) Anthrax Anti-Toxin Studies at the HHS Stakeholders Workshop 2009 & BARDA Industry Day

Elusys Therapeutics, Inc. (Elusys), a privately-held biopharmaceutical company developing antibody-based therapies for the treatment of...

Jun 16, 2009, 08:00 ET
A F ELUSYS THERAPEUTICS, INC. LOGO ELUSYS THERAPEUTICS, INC. LOGO

corporate logo. (PRNewsFoto/Elusys Therapeutics, Inc.)[CH]
 PINE BROOK, NJ UNITED STATES
 04/20/2009

Elusys Therapeutics and Lonza Enter Into Manufacturing Agreement

PINE BROOK, N.J. and BASEL, Switzerland, June 16 /PRNewswire/ -- Elusys Therapeutics and Lonza Sales AG entered into an agreement for the...

Apr 20, 2009, 13:40 ET
A F ELUSYS THERAPEUTICS, INC. LOGO ELUSYS THERAPEUTICS, INC. LOGO

corporate logo. (PRNewsFoto/Elusys Therapeutics, Inc.)[CH]
 PINE BROOK, NJ UNITED STATES
 04/20/2009

Elusys' Anthrax Anti-Toxin, Anthim(TM), Enters Second Phase I Clinical Study

- Anthim Dramatically Improves Survival in Animals with Clinical Symptoms of Anthrax disease - Elusys Therapeutics, Inc. (Elusys), a...

Apr 22, 2008, 01:00 ET

Elusys' Anthim(TM) Dramatically Improves Survival of Animals Treated After Active Anthrax Infection

PINE BROOK, N.J., April 22 /PRNewswire/ -- Elusys Therapeutics, Inc. (Elusys), a privately-held biopharmaceutical company developing...

Mar 10, 2008, 01:00 ET

Elusys Therapeutics Appoints Robert Gundel as Vice President of Research

PINE BROOK, N.J., March 10 /PRNewswire/ -- Elusys Therapeutics, Inc. (Elusys), a privately held biopharmaceutical company developing...

Sep 25, 2007, 01:00 ET

Niaid / Barda Awards Elusys a $12 Million Contract to Further Develop Anthim, the Company's Anthrax Therapeutic

PINE BROOK, N.J., Sept. 25 /PRNewswire/ -- Elusys Therapeutics, Inc. (Elusys), a privately held biopharmaceutical company developing...

Sep 18, 2007, 01:00 ET

Elusys Therapeutics Appoints Robert D. Love as Chief Financial Officer

PINE BROOK, N.J., Sept. 18 /PRNewswire/ -- Elusys Therapeutics, Inc. (Elusys), a privately held biopharmaceutical company developing...